Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.

What Was Tested

The paper reports a study of Hydrochlorothiazide and Lisinopril, published as a randomized controlled trial.

This was a randomized, double-blind, active-controlled, parallel group, multicenter trial involving 129 adult outpatients with essential hypertension.

Who Took Part

The abstract describes 3 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Comparability of response to treatment was assessed by mean sitting diastolic and systolic blood pressure at the end of treatment.

How the Study Was Run

In design terms this was a randomized, double-blind, multicenter and parallel-group study.

Because people in this Hydrochlorothiazide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Hydrochlorothiazide study, the assignments were hidden from both participants and investigators until the end.

Running at several centres spread the Hydrochlorothiazide study over different clinics and patient groups.

Groups ran in parallel: each of the patients stayed in one arm throughout.

What Was Measured

Topics PubMed links to this paper include Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cough, Hydrochlorothiazide, Hypertension and Lisinopril.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Hydrochlorothiazide and Lisinopril in 3 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Journal of clinical pharmacology), a journal based in England.

More context: all human trials.